<?xml version="1.0" encoding="UTF-8"?>
<p>The repurposing of available antiviral drugs, such as the HIV protease inhibitor lopinavir, is a priority. Clinicians from Wuhan conducted an open‐label clinical trial against controls with about 100 patients per arm. No major improvement was seen in the lopinavir group. The negative outcome might be due to the late drug application in severely affected patients (mortality was 25% in the control group). However, since no effect on viral shedding was seen, it was concluded that lopinavir does not inhibit SARS‐CoV‐2 replication 
 <italic>in vivo</italic> (Baden and Rubin, 
 <xref rid="mbt213592-bib-0003" ref-type="ref">2020</xref>; Cao 
 <italic>et al</italic>
 <italic>.</italic>, 
 <xref rid="mbt213592-bib-0009" ref-type="ref">2020</xref>).
</p>
